ublituximab | Ublituximab

Keyword	CPC	PCC	Volume	Score	Length of keyword
ublituximab	1.46	0.5	7803	15	11

Keyword	CPC	PCC	Volume	Score
ublituximab	1.36	0.1	189	12
ublituximab-xiiy	1.54	0.1	5186	88
ublituximab fda approval	0.68	0.5	6629	53
ublituximab ms	1.35	0.5	6760	18
ublituximab ema	0.46	0.3	222	7
ublituximab multiple sclerosis	0.35	0.3	6750	5
ublituximab fda	1.09	0.4	8315	71
ublituximab vs ocrelizumab	0.96	0.6	1504	43
ublituximab package insert	0.14	0.5	7159	60
ublituximab briumvi	1.66	0.2	4873	63
ublituximab approval	0.62	0.8	9950	61
ublituximab vs ocrevus	1.6	0.4	6503	18
ublituximab mechanism of action	0.4	0.6	6159	39

Search Results related to ublituximab on Search Engine

Ublituximab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Ublituximab

WEBUblituximab is indicated for the treatment of relapsing-remitting, active secondary progressive, and clinically isolated syndrome forms of multiple sclerosis in adults. [1] [4] [6] In the European Union, ublituximab is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical ...

DA: 94 PA: 69 MOZ Rank: 5

BRIUMVI ® (ublituximab-xiiy)
briumvi.com

https://briumvi.com/

WEBBRIUMVI ® (ublituximab-xiiy) is available for people with relapsing multiple sclerosis (RMS), the only B-cell therapy for RMS that is administered in 1 hour, twice per year.

DA: 12 PA: 14 MOZ Rank: 40

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2201904

WEBAug 24, 2022 · The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple...

DA: 47 PA: 4 MOZ Rank: 22

Ublituximab: a new anti-CD20 agent for multiple sclerosis
thelancet.com

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00446-X/fulltext

WEBTaken together, ULTIMATE I and II introduce ublituximab as another high-efficacy anti-CD20 agent for relapsing multiple sclerosis, with overall attractive safety and tolerability profiles. Practically, many neurologists will probably use ublituximab initially in a similar manner to other anti-CD20 monoclonal antibodies.

DA: 7 PA: 100 MOZ Rank: 79

Briumvi (ublituximab) in MS | Uses, side effects, and more
multiplesclerosisnewstoday.com

https://multiplesclerosisnewstoday.com/experimental-treatments-for-ms/ublituximab-tgtx-1101/

WEBJan 12, 2023 · Briumvi (ublituximab-xiiy) is an approved antibody-based therapy used to reduce relapses and slow the development of brain lesions in people with relapsing forms of multiple sclerosis (MS)....

DA: 30 PA: 37 MOZ Rank: 12

Ublituximab: Uses, Interactions, Mechanism of Action - DrugBank …
drugbank.com

https://go.drugbank.com/drugs/DB11850

WEBOct 20, 2016 · Ublituximab is a low-fucose CD20-targeted monoclonal antibody used in the treatment of relapsing forms of multiple sclerosis. Brand Names. Briumvi. Generic Name. Ublituximab. DrugBank Accession Number. DB11850. Background.

DA: 26 PA: 17 MOZ Rank: 56

Ublituximab Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/ublituximab.html

WEBApr 18, 2023 · What is ublituximab? Ublituximab is used to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ublituximab may also be used for purposes not listed in this medication guide.

DA: 13 PA: 50 MOZ Rank: 79

Briumvi | European Medicines Agency
europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/briumvi

WEBMar 31, 2023 · ublituximab. Medicine Human. Overview. Briumvi is a medicine for treating adults with relapsing forms of multiple sclerosis (a disease of the brain and spinal cord in which inflammation destroys the protective covering around nerves and damages the nerves), where the patient has flare-ups (relapses) followed by periods with milder or no …

DA: 62 PA: 100 MOZ Rank: 54

Ublituximab: First Approval - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/36920653/

WEBIn December 2022, ublituximab received its first global approval in the USA for the treatment of adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

DA: 9 PA: 34 MOZ Rank: 1

Ublituximab in relapsing forms of multiple sclerosis: a profile of its
springer.com

https://link.springer.com/article/10.1007/s40267-023-01030-z

WEBNov 6, 2023 · Ublituximab (BRIUMVI TM ), an anti-CD20 immunoglobulin G1 monoclonal antibody, is a promising new treatment option for patients with relapsing forms of multiple sclerosis (MS). Ublituximab is approved in the USA and the EU for the treatment of adult patients with relapsing forms of MS.

DA: 60 PA: 6 MOZ Rank: 68